Trial Watch: Immunostimulation with Toll-like receptor agonists in cancer therapy

Accumulating preclinical evidence indicates that Toll-like receptor (TLR) agonists efficiently boost tumor-targeting immune responses (re)initiated by most, if not all, paradigms of anticancer immunotherapy. Moreover, TLR agonists have been successfully employed to ameliorate the efficacy of various...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncoimmunology
Main Authors: Iribarren, Kristina, Bloy, Norma, Buqué, Aitziber, Cremer, Isabelle, Eggermont, Alexander, Fridman, Wolf Hervé, Fucikova, Jitka, Galon, Jérôme, Špíšek, Radek, Zitvogel, Laurence, Kroemer, Guido, Galluzzi, Lorenzo
Formato: Artigo
Idioma:Inglês
Publicado em: Taylor & Francis 2015
Assuntos:
Review
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4839356/
https://ncbi.nlm.nih.gov/pubmed/27141345
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2015.1088631
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados